SEC Filings

SEC Filings

Filing date	Form	Description	Filing Group	View
March 28, 2023	6-K	Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act	Current Reports	0001104659-23-037449.pdf 0001104659-23-037449.rtf 0001104659-23-037449.xls View HTML
March 13, 2023	6-K	Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act	Current Reports	0001104659-23-031570.pdf 0001104659-23-031570.rtf 0001104659-23-031570.xls View HTML
February 21, 2023	6-K	Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act	Current Reports	0001104659-23-023555.pdf 0001104659-23-023555.rtf 0001104659-23-023555.xls View HTML
February 15, 2023	6-K	Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act	Current Reports	0001104659-23-022221.pdf 0001104659-23-022221.rtf 0001104659-23-022221.xls View HTML
February 15, 2023	6-K	Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act	Current Reports	0001104659-23-022411.pdf 0001104659-23-022411.rtf 0001104659-23-022411.xls View HTML
February 14, 2023	SC 13G/A	An amendment to the SC 13G filing	Other	0001213900-23-011501.pdf 0001213900-23-011501.rtf 0001213900-23-011501.xls View HTML
February 13, 2023	6-K	Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act	Current Reports	0001104659-23-019053.pdf 0001104659-23-019053.rtf 0001104659-23-019053.xls View HTML
November 10, 2022	6-K	Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act	Current Reports	0001104659-22-117213.pdf 0001104659-22-117213.rtf 0001104659-22-117213.xls View HTML
November 09, 2022	424B3	Form of prospectus reflecting facts events constituting substantive change from last form	Registration Statements	0001104659-22-116479.pdf 0001104659-22-116479.rtf 0001104659-22-116479.xls View HTML
November 08, 2022	6-K	Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act	Current Reports	0001104659-22-115968.pdf 0001104659-22-115968.rtf 0001104659-22-115968.xls View HTML

In severe or life-threatening conditions where there are no available treatment options, regulators may grant permission to provide a treating physician access to an unapproved drug; this is known as expanded access. At this time, the safety and effectiveness of nomacopan to treat diseases such as Atopic Keratoconjunctivitis (AKC), Bullous Pemphigoid (BP); Thrombotic Microangiopathy (TMA), and Paroxysmal Nocturnal Hemoglobinuria (PNH) has not been established. Until more data are available, Akari Therapeutics is not considering requests for expanded access outside of clinical trials. This policy may change as safety and efficacy are better demonstrated. For questions regarding our current expanded access policy, please contact Akari Therapeutics at +44 (0)20-8004-0261.